NCT07343401Completed
Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development
Impact of Immunosuppressive Therapy of Sarcoidosis on Lymphoma Development
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 7 Jan 2026
- Start date
- 1 Aug 2025
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Alexandria University
- NCT number
- NCT07343401
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 1 Aug 2025 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria main university hospital Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.